See more : Dayton & Michigan Railroad Co. PFD 8% (DMRRP) Income Statement Analysis – Financial Results
Complete financial analysis of Metacrine, Inc. (MTCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Metacrine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aquila Services Group plc (AQSG.L) Income Statement Analysis – Financial Results
- Leform Berhad (0266.KL) Income Statement Analysis – Financial Results
- Speakeasy Cannabis Club Ltd. (EASY.CN) Income Statement Analysis – Financial Results
- ECP Emerging Growth Limited (ECP.AX) Income Statement Analysis – Financial Results
- SUVIDHA INFRAESTATE CORPORATIO (SICL.BO) Income Statement Analysis – Financial Results
Metacrine, Inc. (MTCR)
About Metacrine, Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.45M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 1.45M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 45.47M | 26.79M | 25.97M | 22.94M |
| General & Administrative | 15.61M | 9.90M | 4.03M | 5.24M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.61M | 9.90M | 4.03M | 5.24M |
| Other Expenses | 0.00 | -614.00K | 0.00 | 0.00 |
| Operating Expenses | 61.08M | 36.69M | 30.00M | 28.18M |
| Cost & Expenses | 61.08M | 36.69M | 30.00M | 28.18M |
| Interest Income | 102.00K | 494.00K | 1.42M | 934.00K |
| Interest Expense | 1.20M | 1.01M | 347.00K | 0.00 |
| Depreciation & Amortization | 972.00K | 931.00K | 2.25M | 829.00K |
| EBITDA | -61.08M | -36.69M | -27.76M | -24.99M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,723.59% |
| Operating Income | -61.08M | -36.69M | -30.00M | -26.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,843.38% |
| Total Other Income/Expenses | -1.13M | -614.00K | 1.07M | 908.00K |
| Income Before Tax | -62.21M | -37.30M | -28.93M | -25.82M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -1,780.76% |
| Income Tax Expense | -972.00K | -931.00K | 347.00K | 908.00K |
| Net Income | -61.24M | -36.37M | -29.28M | -25.82M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -1,780.76% |
| EPS | -1.45 | -3.87 | -1.52 | -1.35 |
| EPS Diluted | -1.45 | -3.87 | -1.52 | -1.35 |
| Weighted Avg Shares Out | 42.11M | 9.40M | 19.22M | 19.06M |
| Weighted Avg Shares Out (Dil) | 42.11M | 9.40M | 19.22M | 19.06M |
Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH
Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant...
Metacrine Reports Positive Results from Phase 1 Trial of MET642
MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase
Metacrine to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief...
U.S. IPO Week Ahead: The IPO Market Braces For A September SNOWstorm In A 12-IPO Week
The post-Labor Day IPO frenzy is here as 12 IPOs plan to raise $6.8 billion in the coming week, led by cloud data unicorn Snowflake.
IPO Update: Metacrine Seeks $85 Million U.S. IPO
Metacrine has filed to raise $85 million in an IPO of its common stock. The firm is developing treatments for NASH, a liver disease whose prevalence is increasing rapidly.
Metacrine Seeks U.S. IPO For NASH Pipeline Advance
Metacrine has filed to raise $100 million in an IPO. The firm is developing treatments for NASH and other GI diseases.
U.S. IPO Weekly Recap: The IPO Market Gears Up For Fall With Wave Of Filings In A 2 IPO Week
Two foreign electric vehicle makers and three SPACs went public this past week. A wave of filings brought 27 companies into the IPO pipeline.
Source: https://incomestatements.info
Category: Stock Reports